What We Do
Clinical Trial Partnerships
BluMaiden Biosciences partners with Pharma, Biotech, and Clinical Institutions on clinical trials and clinical studies by adding the value of microbiome endpoints. Our state-of-the-art genome-resolved metagenome analysis workflows provide high quality microbiome analysis for any type of clinical trial anywhere in the world. We partner on all type of study designs and sizes. Among the many potential outputs, microbiome analysis can yield actionable information on patient stratification, effects of microbiome on drug efficacy, and the impact of drug interventions on microbiome.
Digital Health Platform Out-licensing
Drug Discovery
The multi-platform technologies built by BluMaiden Biosciences integrate to enable discovery of microbiome-derived small molecule drugs. The technologies allow for exploration and collaboration in areas such as clinical data-derived functional gene screening, AI-driven chemical space screening, and in silico ligand and target selection. Building on early R&D activities and engagements through the MAIDEN platform, BluMaiden Biosciences has developed an internal pipeline of disease focus areas. The Company is actively partnering in platform collaborations and/or drug asset discovery projects with Pharma and Biotech.
Get In Touch
If you have a general question for us or want to explore a partnership opportunity, then please reach out to us here.
